WithdrawnPhase 1NCT02427178

MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study

Studying Mitochondrial neurogastrointestinal encephalomyopathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Michio Hirano, MD
Principal Investigator: Michio Hirano, MD
Columbia University
Intervention: Hematopoietic Allogeneic Stem Cells(biological)
Eligibility: 5-55 years · All sexes
Timeline: 2015 – 2023

Collaborators

Cornell University · National Institute of Neurological Disorders and Stroke (NINDS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02427178 on ClinicalTrials.gov

← Back to all trials